Speculating on the basis of the abundant presence of SIGLEC ligands on tumor cell surfaces, coupled with the inhibitory characteristics demonstrated by numerous SIGLECs (14), we propose SIGLEC7 as a potentially promising immunotherapeutic target for glioma. This evidence concerns the gene SIGLEC7 and central nervous system cancer.